Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease

被引:0
|
作者
Morales Bermudez, A. I. [1 ]
Bracho Gonzalez, M. [1 ]
Gomez Rodriguez, P. [1 ]
Olmedo Martin, R. [1 ]
机构
[1] Reg Univ Hosp Malaga, Digest Dis Dept, Malaga, Spain
来源
关键词
D O I
暂无
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
P541
引用
收藏
页码:I489 / I490
页数:2
相关论文
共 50 条
  • [1] Effectiveness, safety and durability of vedolizumab in active moderate-severe Crohn's Disease
    Morales Bermudez, A. I.
    Bracho Gonzalez, M.
    Gomez Rodriguez, P.
    Olmedo Martin, R.
    [J]. JOURNAL OF CROHNS & COLITIS, 2022, 16 : I489 - I490
  • [2] The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium
    Dulai, Parambir S.
    Singh, Siddharth
    Jiang, Xiaoqian
    Peerani, Farhad
    Narula, Neeraj
    Chaudrey, Khadija
    Whitehead, Diana
    Hudesman, David
    Lukin, Dana
    Swaminath, Arun
    Shmidt, Eugenia
    Wang, Shuang
    Boland, Brigid S.
    Chang, John T.
    Kane, Sunanda
    Siegel, Corey A.
    Loftus, Edward V.
    Sandborn, William J.
    Sands, Bruce E.
    Colombel, Jean-Frederic
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (08): : 1147 - 1155
  • [3] Ustekinumab versus Vedolizumab for Moderate to Severe Crohn's Disease
    Singh, Amandeep
    Khan, Freeha
    Lopez, Rocio
    Shen, Bo
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S393 - S394
  • [4] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn's Disease in China
    Zhou, Ting
    Sheng, Yanan
    Guan, Haijing
    [J]. ADVANCES IN THERAPY, 2021, 38 (08) : 4233 - 4245
  • [5] Cost-Effectiveness of Vedolizumab in the Treatment of Moderate-to-Severe Crohn’s Disease in China
    Ting Zhou
    Yanan Sheng
    Haijing Guan
    [J]. Advances in Therapy, 2021, 38 : 4233 - 4245
  • [6] The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review
    Avedillo-Salas, Ana
    Corral-Cativiela, Sara
    Fanlo-Villacampa, Ana
    Vicente-Romero, Jorge
    [J]. PHARMACEUTICALS, 2023, 16 (11)
  • [7] The Value of Vedolizumab as Rescue Therapy in Moderate-Severe Crohn's Disease Patients with Adalimumab Non-response in the USA
    Erim, Daniel O.
    Mahendraratnam, Nirosha
    Okafor, Phillip N.
    Wheeler, Stephanie B.
    [J]. JOURNAL OF CROHNS & COLITIS, 2015, 9 (08): : 669 - 675
  • [8] REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE
    Lee, Scott D.
    Singla, Anand
    Kerwin, Caitlin
    Clark-Snustad, Kindra
    [J]. GASTROENTEROLOGY, 2020, 158 (03) : S121 - S122
  • [9] REAL-WORLD EXPERIENCE: CLINICAL AND ENDOSCOPIC EFFECTIVENESS OF STANDARD VEDOLIZUMAB DOSING AND MODIFIED MAINTENANCE DOSING IN PATIENTS WITH MODERATE-SEVERE CROHN'S DISEASE
    Lee, Scott D.
    Singla, Anand
    Kerwin, Caitlin
    Clark-Snustad, Kindra
    [J]. INFLAMMATORY BOWEL DISEASES, 2020, 26 : S75 - S75
  • [10] Comparing the Efficacy and Safety of Adalimumab and Vedolizumab in Treating Moderate to Severe Crohn's Disease and Ulcerative Colitis
    Merza, Nooraldin
    Nawras, Yusuf
    Saab, Omar
    Dahiya, Dushyant Singh
    Ahmed, Zohaib
    Ranabothu, Meghana
    Boujemaa, Safa
    Hassan, Mona
    Kobeissy, Abdallah
    Lilley, Kirthi
    [J]. GASTROENTEROLOGY RESEARCH, 2023, 16 (06) : 289 - 306